Detalles de la búsqueda
1.
The effect of food and acid-reducing agents on the pharmacokinetic profile of capivasertib: Results from a randomized, crossover study.
Br J Clin Pharmacol
; 89(11): 3330-3339, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37328269
2.
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
Br J Clin Pharmacol
; 88(2): 858-864, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34309049
3.
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38643311
4.
Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.
Clin Pharmacol Drug Dev
; 12(9): 856-862, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37449963
5.
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
; 21(2): 278-285, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36572571
6.
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 26(7): 1574-1585, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31836609
7.
Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.
Drugs R D
; 18(2): 149-159, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29856004
8.
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Cancer Chemother Pharmacol
; 81(5): 873-883, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29541803
9.
A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.
Clin Cancer Res
; 24(9): 2050-2059, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066505
10.
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Clin Cancer Res
; 23(18): 5366-5373, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28615371
11.
Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT).
Clin Cancer Res
; 28(24): 5469, 2022 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36519303
12.
In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.
Clin Pharmacol Drug Dev
; 5(5): 364-73, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27627192
13.
Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
Lancet Respir Med
; 4(10): 797-806, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27574788
14.
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.
Clin Pharmacol Ther
; 77(4): 279-90, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15903126
15.
No effect of encapsulation on the pharmacokinetics of warfarin.
Biopharm Drug Dispos
; 26(3): 121-7, 2005 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15751004
16.
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Eur J Clin Pharmacol
; 59(4): 283-9, 2003 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12845508
Resultados
1 -
16
de 16
1
Próxima >
>>